Skip to content
10-Q

Quarterly Report

VITRO BIOPHARMA, INC.

0001641172-25-027168

← back to feed
Filed
Sep 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Sep 12, 2025 4.46M sh
Shares Diluted Q3 2025 · Jul 31, 2025 4.46M sh
Shares Diluted Q3 2025 · Jul 31, 2025 4.46M sh
Shares Diluted Q3 2025 · Jul 31, 2024 4.46M sh
Shares Diluted Q3 2025 · Jul 31, 2024 4.46M sh
Capex Q3 2025 · Jul 31, 2025 $1.31K
Operating Cash Flow Q3 2025 · Jul 31, 2025 −$1.8M
Operating Cash Flow Q3 2025 · Jul 31, 2024 −$2.28M
Long Term Debt Q3 2025 · Jul 31, 2025 $1.16M
Long Term Debt Q3 2025 · Oct 31, 2024 $3.05M
Short Term Debt Q3 2025 · Jul 31, 2025 $4.27M
Short Term Debt Q3 2025 · Oct 31, 2024 $5.2M
Stockholders Equity Q3 2025 · Jul 31, 2025 −$12.08M
Stockholders Equity Q3 2025 · Apr 30, 2025 −$11.07M
Stockholders Equity Q3 2025 · Jan 31, 2025 −$9.91M
Stockholders Equity Q3 2025 · Oct 31, 2024 −$9M
Stockholders Equity Q3 2025 · Jul 31, 2024 −$7.32M
Stockholders Equity Q3 2025 · Apr 30, 2024 −$7.56M
Stockholders Equity Q3 2025 · Jan 31, 2024 −$4.83M
Stockholders Equity Q3 2025 · Oct 31, 2023 −$1.09M
Current Liabilities Q3 2025 · Jul 31, 2025 $14.93M
Current Liabilities Q3 2025 · Oct 31, 2024 $10.06M
Total Liabilities Q3 2025 · Jul 31, 2025 $16.71M
Total Liabilities Q3 2025 · Oct 31, 2024 $14.09M
Current Assets Q3 2025 · Jul 31, 2025 $645.41K
Current Assets Q3 2025 · Oct 31, 2024 $975.75K
Total Assets Q3 2025 · Jul 31, 2025 $4.63M
Total Assets Q3 2025 · Oct 31, 2024 $5.09M
Eps Diluted Q3 2025 · Jul 31, 2025 −$0.38
Eps Diluted Q3 2025 · Jul 31, 2025 −$1.35
Eps Diluted Q3 2025 · Jul 31, 2024 −$0.03
Eps Diluted Q3 2025 · Jul 31, 2024 −$1.76
Eps Basic Q3 2025 · Jul 31, 2025 −$0.38
Eps Basic Q3 2025 · Jul 31, 2025 −$1.35
Eps Basic Q3 2025 · Jul 31, 2024 −$0.03
Eps Basic Q3 2025 · Jul 31, 2024 −$1.76
Sga Expense Q3 2025 · Jul 31, 2025 $1.31M
Sga Expense Q3 2025 · Jul 31, 2025 $4.67M
Sga Expense Q3 2025 · Jul 31, 2024 $1.38M
Sga Expense Q3 2025 · Jul 31, 2024 $5.07M
Rd Expense Q3 2025 · Jul 31, 2025 $119.21K
Rd Expense Q3 2025 · Jul 31, 2025 $415.52K
Rd Expense Q3 2025 · Jul 31, 2024 $125.63K
Rd Expense Q3 2025 · Jul 31, 2024 $421.55K
Net Income Q3 2025 · Jul 31, 2025 −$1.7M
Net Income Q3 2025 · Jul 31, 2025 −$6.01M
Net Income Q3 2025 · Apr 30, 2025 −$1.48M
Net Income Q3 2025 · Jan 31, 2025 −$2.83M
Net Income Q3 2025 · Jul 31, 2024 −$149.08K
Net Income Q3 2025 · Jul 31, 2024 −$7.84M
Net Income Q3 2025 · Apr 30, 2024 −$3.12M
Net Income Q3 2025 · Jan 31, 2024 −$4.57M
Operating Income Q3 2025 · Jul 31, 2025 −$890.11K
Operating Income Q3 2025 · Jul 31, 2025 −$3.82M
Operating Income Q3 2025 · Jul 31, 2024 −$1.25M
Operating Income Q3 2025 · Jul 31, 2024 −$7.08M
Gross Profit Q3 2025 · Jul 31, 2025 $539.03K
Gross Profit Q3 2025 · Jul 31, 2025 $1.27M
Gross Profit Q3 2025 · Jul 31, 2024 $254.47K
Gross Profit Q3 2025 · Jul 31, 2024 $1.07M
Cost Of Revenue Q3 2025 · Jul 31, 2025 $69.61K
Cost Of Revenue Q3 2025 · Jul 31, 2025 $297.53K
Cost Of Revenue Q3 2025 · Jul 31, 2024 $65.44K
Cost Of Revenue Q3 2025 · Jul 31, 2024 $244.8K
Revenue Q3 2025 · Jul 31, 2025 $608.64K
Revenue Q3 2025 · Jul 31, 2025 $1.57M
Revenue Q3 2025 · Jul 31, 2024 $319.91K
Revenue Q3 2025 · Jul 31, 2024 $1.32M